Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some patients, ICI efficacy remains reserved to a subgroup that is not yet fully characterized. Tissue based assays, such as Programm...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancers (Basel)
Päätekijät: Duchemann, Boris, Remon, Jordi, Naigeon, Marie, Mezquita, Laura, Ferrara, Roberto, Cassard, Lydie, Jouniaux, Jean Mehdi, Boselli, Lisa, Grivel, Jonathan, Auclin, Edouard, Desnoyer, Aude, Besse, Benjamin, Chaput, Nathalie
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2020
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7761725/
https://ncbi.nlm.nih.gov/pubmed/33287347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123625
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia